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OBJECTIVES The purpose of this randomized study was to evaluate the prevalence of pocket hematomas
in patients treated with heparin 6 h or 24 h after pacemaker or defibrillator implantation.
BACKGROUND The risks of pocket hematoma and need for evacuation after device implantation have not
been defined in patients who require anticoagulation.
METHODS Forty-nine consecutive patients with an indication for anticoagulation with heparin after
implantable defibrillator or pacemaker implantation were randomized to receive intravenous
heparin either 6 h (n 5 26) or 24 h (n 5 23) postoperatively. Both groups also received
warfarin on a daily basis starting the evening of surgery. Twenty-eight patients who received
postoperative warfarin alone and 115 patients who did not receive anticoagulation were
followed up in a study registry.
RESULTS A pocket hematoma developed in 6 of 26 patients (22%) who were treated with intravenous
heparin 6 h postoperatively, as compared with 4 of 23 patients (17%) who were treated with
intravenous heparin 24 h postoperatively (p 5 0.7). In total, a pocket hematoma developed
in 10 of 49 patients (20%) treated with heparin, 1 of 28 patients (4%) treated with warfarin
alone and 2 of 115 (2%) patients who received no anticoagulation (p , 0.001).
CONCLUSIONS Intravenous heparin initiation 6 h or 24 h after pacemaker or defibrillator implantation is
associated with a 20% prevalence of pocket hematoma formation. Warfarin therapy or no
anticoagulation is associated with only a 2% to 4% risk of pocket hematoma formation. (J Am
Coll Cardiol 2000;35:1915–8) © 2000 by the American College of Cardiology
Anticoagulation is used to prevent thromboembolic com-
plications in high risk patients with atrial fibrillation (AF),
a mechanical prosthetic valve or poor left ventricular func-
tion. The use of intravenous anticoagulation with heparin
immediately after pacemaker or defibrillator implantation is
associated with a poorly-defined risk of pocket hematoma
formation. Based on the daily risk of arterial thromboem-
bolism calculated from the yearly risk in patients with
nonrheumatic AF or a prosthetic heart valve, some investi-
gators have strongly recommended against the perioperative
use of intravenous heparin, since the perioperative bleeding
risk is greatly increased (1). The purpose of this study was to
define the prevalence of postoperative pocket hematoma
formation and need for hematoma evacuation associated
with heparin, warfarin or no anticoagulation.
METHODS
Patient characteristics. The subjects of this prospective
study were 192 consecutive patients at the University of
Michigan Medical Center who received an implantable
defibrillator or a permanent pacemaker between February
1997 and July 1998. Patients undergoing replacement of a
pacemaker or implantable defibrillator generator were ex-
cluded. The patients consisted of 136 men and 56 women
with a mean age of 64 6 14 years and mean ejection fraction
of 0.40 6 0.17. Forty-seven percent of patients had coro-
nary artery disease, 25% had no structural heart disease, 14%
had nonischemic dilated cardiomyopathy, 9% had aortic or
mitral valve disease, 3% had received a heart transplant, 1%
had hypertrophic cardiomyopathy and 1% had congenital
anomalies. Seventy-eight patients received a dual-chamber
pacemaker, 35 patients received a single-chamber pace-
maker, 60 patients received a single-chamber implantable
defibrillator, 12 patients received a dual-chamber implant-
able defibrillator, and 7 patients received both a pacemaker
and implantable defibrillator. All pacemakers and defibril-
lators were implanted in a prepectoral pocket.
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Forty-nine patients had an indication for intravenous anti-
coagulation and were randomized to receive intravenous hep-
arin 6 h or 24 h postoperatively. Among these 49 patients, 18
had a mechanical heart valve, 30 had chronic AF and 1 had a
deep venous thrombosis within the previous month. Twenty-
eight patients received warfarin long term but did not have an
indication for immediate postoperative anticoagulation with
heparin. One hundred fifteen patients did not receive intrave-
nous heparin or warfarin following the surgical procedure.
Aspirin therapy was not altered for surgery. Overall, 50% of
patients (97/192) were treated with aspirin (mean daily dosage
of 228 6 120 mg/d) at the time of the surgical procedure.
Twenty-nine percent of patients (14/49) who received postop-
erative heparin, 36% of patients (10/28) who received warfarin
alone starting the evening of the procedure and 63% of patients
(73/115) who did not receive anticoagulation were receiving
aspirin at the time of the surgical procedure (p , 0.001). Only
three patients were receiving both ticlopidine and aspirin.
There were no identifiable differences in clinical charac-
teristics among patients treated with the two heparin dosing
schedules. There were also no identifiable differences in
clinical characteristics or type of implanted device between
patients treated with heparin, warfarin or no anticoagula-
tion. However, patients with a mechanical heart valve were
more likely to receive intravenous heparin (p , 0.001), and
patients who did not receive intravenous heparin or warfarin
were more likely to receive aspirin (p , 0.001).
Study protocol. The study was approved by the Human
Research Committee at the University of Michigan Medical
Center. Patients who were not randomized to receive
heparin therapy were entered into the study registry. Treat-
ment with warfarin and heparin was discontinued at least
three days and 6 h, respectively, before the pacemaker or
defibrillator implantation procedure. All patients had an
international normalized ratio (INR) ,1.5 on the day of
surgery. Patients with an indication for postoperative intra-
venous anticoagulation were randomized to receive intrave-
nous heparin starting either 6 h or 24 h following device
implantation. Postoperative intravenous heparin was in-
fused at 1,000 U/h without a bolus dose or at a previously
identified infusion rate that maintained the partial throm-
boplastin time between 1.5 and 2.0 times the control value.
The partial thromboplastin time was measured 6 h after the
initiation of heparin therapy and after dosage adjustments,
which were made according to a standardized nomogram
used at the University of Michigan Medical Center. War-
farin therapy was reinstituted the night of the surgical
procedure in all patients in whom it was discontinued
preoperatively. Infusion of heparin was discontinued when
the INR reached $2.0. Patients were examined daily until
hospital discharge, and then one week and two months after
implantation. Systemic thromboembolic events were as-
sessed over the same time period. A pocket hematoma was
defined by two investigators as a palpable mass that pro-
truded $2 cm anterior to the pulse generator and lead(s).
A pocket hematoma was evacuated if tense swelling
caused poor capillary perfusion of the overlying skin or
severe pain or if the hematoma enlarged progressively.
Patients were instructed to contact one of the investigators
if a hematoma developed after hospital discharge.
Statistical analysis. Continuous variables are expressed as
mean 6 1 SD. Continuous variables were analyzed using a t
test or analysis of variance with repeated measures, as appro-
priate. Nominal variables were compared using a chi-square
analysis. A Mann-Whitney U nonparametric test was used to
evaluate data that did not have a normal distribution. A
probability value ,0.05 was considered statistically significant.
Kaplan-Meier log-rank analysis was performed to assess free-
dom from postoperative pocket hematoma formation for
patients grouped by anticoagulation status.
RESULTS
Evacuation of a pocket hematoma. Evacuation of a
pocket hematoma was necessary in 2 of 49 (4%) patients
treated with heparin, 1 of 28 (4%) patients treated with
warfarin (Coumadin) and 1 of 115 (1%) patients who
received no anticoagulation (p 5 0.4).
Prevalence of pocket hematomas. A pocket hematoma
developed in 6 of 26 patients (23%) who received intrave-
nous heparin 6 h postoperatively and warfarin the evening of
surgery, as compared with 4 of 23 patients (17%) who
received intravenous heparin 24 h postoperatively and war-
farin the evening of surgery (p 5 0.7). Among the 49
patients treated with intravenous heparin, 10 (20%) devel-
oped a pocket hematoma, compared with 1 of 28 patients
(4%) treated with warfarin alone and 2 of 115 patients (2%)
who did not undergo anticoagulation (p , 0.001). Figure 1
shows the time course of freedom from postoperative pocket
hematoma formation in patients grouped by anticoagulation
status. The mean time to hematoma formation was 5.1 6
5.8 days (median, 3 days; range, 1 to 20 days) and did not
differ among groups (p 5 0.4). Pocket hematoma formation
was not associated with age (p 5 0.7), gender (p 5 0.4), left
ventricular ejection fraction (p 5 0.6), type of heart disease
(p 5 0.3), type of device implanted (p 5 0.1), number of
leads implanted (p 5 0.3), subclavian vein puncture or
cephalic vein dissection for lead placement (p 5 0.4),
concomitant aspirin therapy (p 5 0.6) or the maximum
partial thromboplastin time value (p 5 0.7). None of the
patients taking ticlopidine alone or ticlopidine and aspirin
developed a postoperative pocket hematoma.
Postoperative days in the hospital. Patients who were
treated with heparin remained in the hospital a mean of 3.6 6
Abbreviations and Acronyms
AF 5 atrial fibrillation
INR 5 international normalized ratio
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2.9 postoperative days compared with a mean of 2.3 6 1.1
postoperative days in patients treated with warfarin alone and
a mean of 2.5 6 2.5 postoperative days in patients receiving no
anticoagulation (p 5 0.02). The 13 patients who developed a
pocket hematoma remained in the hospital a mean of 5.1 6
4.6 postoperative days, compared with a mean of 2.6 6 2.2
days in the 179 patients who did not develop a pocket
hematoma (p 5 0.02). The 10 patients treated with heparin
who developed a pocket hematoma stayed in the hospital a
mean of 5.9 6 5.0 postoperative days, compared with a mean
of 3.6 6 2.9 postoperative days in the 39 patients treated with
heparin who did not develop a pocket hematoma (p 5 0.02).
Thromboembolic complications. A patient with dilated
cardiomyopathy and chronic AF who received warfarin
alone developed a stroke two days postoperatively. No other
patients had symptoms or signs of an arterial or venous
thromboembolic event. One patient who did not receive
anticoagulation died of pulmonary edema one day after a
pacemaker implantation.
DISCUSSION
Major findings. The risk of requiring a pocket hematoma
evacuation following pacemaker or defibrillator implantation
did not differ significantly with regard to anticoagulation status.
Nevertheless, patients who received heparin after pacemaker or
defibrillator implantation had a 5-fold and 10-fold greater risk
of pocket hematoma formation than did patients treated with
warfarin alone or no anticoagulation, respectively. The risk was
the same (17% to 23%) whether heparin therapy was initiated
6 h or 24 h after surgery. Aspirin therapy did not affect the risk
of hematoma formation in patients undergoing pacemaker or
defibrillator implantation.
Patients treated with intravenous heparin following pace-
maker or defibrillator implantation had a longer postoper-
ative hospital stay than patients treated with warfarin alone
or no anticoagulation. Additionally, patients who developed
a pocket hematoma stayed longer after the implantation
than patients who did not develop a hematoma. Even
among those treated with heparin, patients with a pocket
hematoma stayed in the hospital more postoperative days
than patients without a hematoma.
Mechanism of pocket hematoma formation. The only
identifiable risk factor for pocket hematoma formation was
the use of intravenous heparin. The partial thromboplastin
time did not correlate with pocket hematoma formation, as
might be expected, since the partial thromboplastin time
value is an indicator of the degree of anticoagulation
afforded by intravenous heparin. The use of warfarin alone
conferred a much lower risk of pocket hematoma formation,
perhaps because warfarin therapy usually requires at least
three days to achieve a therapeutic level of anticoagulation.
Previous studies. To our knowledge, these are the first
published data demonstrating the high risk of developing a
pocket hematoma in patients receiving heparin after pace-
maker or defibrillator implantation. Pocket hematomas may
require surgical drainage and are associated with discomfort
and an increased risk of infection (2–4). In the present
study, the incidence of pocket hematoma formation among
patients who did not receive anticoagulation was 2%, and
was similar to that observed in previous reports (5,6).
The risk of an arterial thromboembolic event with a
prosthetic heart valve in the absence of anticoagulation is
8% per year (7,8). The average risk for an arterial throm-
boembolic event in a patient with nonvalvular atrial fibril-
lation is 4.5% per year (9). This risk may be as high as 20%
if hypertension, prior stroke, advanced age or congestive
heart failure is present (9,10). Based on these figures, the
calculated daily risk ranges from 0.01% to 0.05%. Heparin
would be expected to reduce venous and arterial thrombo-
embolic risk by 66% to 80% (1). Patients who have
experienced a deep venous thrombosis or arterial thrombo-
embolism within the past month, however, have a much
higher monthly risk of recurrence, 50% and 15%, respec-
tively (1).
Limitations. Because of the small number of end point
events and small sample sizes, the risk-benefit ratio of
postoperative heparin use, that is, pocket hematoma forma-
tion versus prevention of thromboembolic complications,
could not be assessed.
Right atrial pressure was not determined in this study.
Hence, right atrial pressure cannot be addressed as a risk
factor for hematoma formation.
Only two postoperative time intervals for heparin therapy
initiation were chosen for randomization to minimize the
exposure period without anticoagulation. Other intervals such
as 36 h or 48 h may have been associated with fewer pocket
hematomas.
Clinical implications. The use of heparin after pacemaker
or defibrillator implantation is associated with a 20% risk of
Figure 1. Kaplan-Meier analysis showing a statistically significant
difference in freedom from pocket hematoma formation among
patients treated with heparin, warfarin or no anticoagulation
postoperatively (p , 0.0001).
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pocket hematoma formation and a longer postoperative
hospital stay, but it is not associated with an increased risk
of hematoma evacuation when compared to patients treated
with warfarin alone or no anticoagulation. Additionally, a
pocket hematoma is independently associated with an in-
creased postoperative hospital stay. These risks, and the risk
of infection and discomfort associated with a pocket hema-
toma, must be weighed against the small, increased risk of
arterial thromboembolism during the few days it takes to
achieve therapeutic anticoagulation with warfarin. Since an
increased risk of infection, longer hospital stay and greater
postoperative discomfort are trivial compared with a debil-
itating stroke, patients at the highest risk of thromboem-
bolism should have postoperative heparin therapy initiated
6 h to 24 h after pacemaker or defibrillator implantation.
Further studies are needed to elucidate the role of newer
anticoagulation agents, such as low-molecular-weight hep-
arin, and the use of drains to prevent hematoma formation.
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